Peptides by condition · Heart, kidneys and lungs
Peptides studied for obstructive sleep apnea
Checked against our study pages and the FDA labelsPublished by PepVault
Our library holds 4 study pages on obstructive sleep apnea: 4 in people (all meta-analyses or randomized trials). They studied 2 compounds, with this many study pages each: Tirzepatide 3 and Retatrutide 1.
What the research on obstructive sleep apnea looks like
Obstructive sleep apnea is breathing that stops and starts during sleep because the throat closes, again and again through the night. It is closely tied to excess weight, which narrows the airway, and it leaves people tired by day and strains the heart and blood pressure. The peptide research on it comes from weight-loss trials of the newer GLP-1 drugs in adults with obesity and sleep apnea.
Sleep apnea trials count the apnea-hypopnea index (AHI), how many times an hour breathing stops or turns shallow, in an overnight sleep study. They also ask about sleepiness, daytime function and quality of life on questionnaires, and some measure how much oxygen in the blood dropped during the night.
These were trials of weight-loss drugs, so check how much of the change in breathing followed the weight lost. Some people in them used a CPAP machine, the mask that keeps the airway open at night, and some did not; the trials looked at those groups separately, and a result in one may not hold in the other. A subgroup of a larger trial is weaker evidence than a trial built for sleep apnea.

Model. Individual results vary.
The 4 studies, by compound
Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.
Tirzepatide
3 in peopleFor obstructive sleep apnea, 3 of our study pages are filed under Tirzepatide: 3 randomized trials in people. Its studies in people do not give their size on our pages. They were published from 2024 to 2025, in Sleep Med and N Engl J Med.
FDA-approved, with a use tied to obstructive sleep apnea on its label: Zepbound (injection) for weight loss and keeping it off, and moderate to severe obstructive sleep apnea in adults with obesity. Under Mounjaro it is approved for other uses.
- Randomized trial in people · 2025Tirzepatide: sleep apnea gains beat placebo by week 20 in SURMOUNT-OSA
- Randomized trial in people · 2025Tirzepatide: better sleep and quality of life scores in SURMOUNT-OSA
- Randomized trial in people · 2024Tirzepatide: AHI fell 25.3 and 29.3 events per hour in SURMOUNT-OSA
Retatrutide
1 in peopleFor obstructive sleep apnea, 1 of our study pages is filed under Retatrutide: 1 randomized trial in people. It enrolled 2,339 people and was published in 2026, in N Engl J Med.
Retatrutide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug.
- Randomized trial in people · 2,339 people · 2026Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1
Side by side
For the 2 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).
| Compound | In people | Animals or cells | Largest in people | FDA |
|---|---|---|---|---|
| Tirzepatide | 3 | 0 | — | Approved, a use tied to it |
| Retatrutide | 1 | 0 | 2,339 | Not approved |
- In people
- 3
- Animals or cells
- 0
- Largest in people
- —
- FDA
- Approved, a use tied to it
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 2,339
- FDA
- Not approved
What the studies did not show
Each study page names its own limits. These are the questions still open, in the study pages’ words.
- Tirzepatide: sleep apnea gains beat placebo by week 20 in SURMOUNT-OSAThis was a post hoc analysis, so it was not the trial's main test. It shows that improvement went along with weight loss, but it could not separate the effect of weight loss from other effects of tirzepatide. The authors say more research is needed on that question.
- Tirzepatide: better sleep and quality of life scores in SURMOUNT-OSAThese are self-reported questionnaire results over 52 weeks in people with moderate-to-severe sleep apnea and obesity, so they may not apply to milder sleep apnea or to people without obesity. The sleepiness result was significant in Study 1 only.
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1The trial included only adults without diabetes, and the knee and sleep apnea results come from smaller subgroups. It was funded by Eli Lilly.
This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.
Questions
Which peptides have been studied for obstructive sleep apnea?
Our 4 study pages on obstructive sleep apnea are filed under 2 compounds, with this many each: Tirzepatide 3 and Retatrutide 1. Tirzepatide has the most.
Have any been tested in people with obstructive sleep apnea?
Yes: all 4 were in people, all of them meta-analyses or randomized trials (Tirzepatide and Retatrutide). The largest enrolled 2,339 people: “Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1” (2026).
Is any peptide FDA-approved for obstructive sleep apnea?
Yes, with a use tied to obstructive sleep apnea on their FDA labels: Tirzepatide as Zepbound. 1 other compound here with an FDA record has no use tied to it.
How large were the studies in people on obstructive sleep apnea?
Of the 4 in people, 1 gives its size on our pages: 1 had 1,000 people or more. The largest, a randomized trial from 2026, enrolled 2,339.
What is the newest study on obstructive sleep apnea here?
Of our study pages on obstructive sleep apnea, the newest is “Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1”, a randomized trial in people published in 2026.
How this page was built
A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.
Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.